BKM120 and olaparib can be co-administered, but the combination requires attenuation of the BKM120 dose. Clinical benefit was observed in both gBRCAm and gBRCAwt pts. Randomized phase II studies will be needed to further define the efficacy of PI3K/PARP-inhibitor combinations as compared with a PARP inhibitor alone.
Background: HRD is associated with improved efficacy of PARP inhibitors (PARPi), but interaction between HRD and combined anti-angiogenics and PARPi is unclear.We explored several measures of HRD and clinical outcomes from NRG-GY004 (Liu, ASCO 2020). abstracts Annals of Oncology Volume 32 -Issue S5 -2021 S1309
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.